Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Medtech Acquisition Corp Cl A (MTAC)

Medtech Acquisition Corp Cl A (MTAC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
TriSalus Life Sciences Presents New Data at AACR for SD-101 Delivered by the Proprietary PEDD™ Method in Stage IV Uveal Melanoma Patients With Liver Metastases

TriSalus Life Sciences ® Inc., (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with...

MTAC : 11.34 (+18.67%)
TriSalus Life Sciences Appoints James Alecxih to Lead Device Technology Business

TriSalus Life Sciences ® , Inc. (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with...

MTAC : 11.34 (+18.67%)
TriSalus Life Sciences Posts Updated Investor Presentation Highlighting Additional Phase 1 and 1b Clinical Data for Pressure-Enabled Regional Immuno-Oncology™-01 and -02 Studies

TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with...

MTAC : 11.34 (+18.67%)
TriSalus Life Sciences Highlights Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) Clinical Trial Progress and Pre-clinical Research Developments

TriSalus Life Sciences ® , Inc. (“TriSalus” or the “company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with...

MTAC : 11.34 (+18.67%)
TriSalus Life Sciences Provides Updates on Pressure-Enabled Regional Immuno-Oncology™ (PERIO™) 01 and 02 Clinical Studies

TriSalus Life Sciences®, Inc. (“TriSalus”) (the “Company”), an oncology therapeutics company in the process of going public through a business combination transaction (the “Business Combination”)...

MTAC : 11.34 (+18.67%)
TriSalus Life Sciences to Become Publicly Traded Through Merger With MedTech Acquisition Corporation

TriSalus Life Sciences® (the “Company” or “TriSalus”), a privately held oncology therapeutics company integrating immunotherapy with disruptive delivery technology to transform the treatment...

MTAC : 11.34 (+18.67%)
MedTech Acquisition Corporation and Memic Innovative Surgery Ltd. Mutually Agree to Terminate Business Combination

TEL AVIV, Israel and FORT LAUDERDALE, Fla., March 10, 2022 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech”), a publicly...

MTAC : 11.34 (+18.67%)
Moore Kuehn Encourages FRSG, MTAC, SLCR, and ADF Investors to Contact Law Firm

NEW YORK, Sept. 03, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning...

FRSG : 10.15 (-0.10%)
MTAC : 11.34 (+18.67%)
SLCR : 7.99 (+1.78%)
ADF : 10.66 (+4.51%)
MedTech Acquisition Corporation Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

New York, NY, June 02, 2021 (GLOBE NEWSWIRE) -- MedTech Acquisition Corporation (Nasdaq: MTACU) (the “Company”) today announced that it has received a notice (“Notice”) from the Listing Qualifications...

MTAC : 11.34 (+18.67%)
MTACW : 0.2180 (+21.11%)
MTACU : 11.35 (+19.47%)

Barchart Exclusives

1 Dividend Aristocrat to Bet on Trump's Tariffs and the Fed's Rate Cuts
Nucor is one stock that stands to benefit from the Fed's rate cuts as well as any possible tariffs under a Trump administration. It is also a dividend aristocrat, and has increased its payouts for over 5 decades. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar